Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,952 shares of the medical instruments supplier’s stock after selling 190 shares during the period. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $897,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of BDX. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $33,000. Tompkins Financial Corp increased its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $229.50 on Wednesday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The firm has a market capitalization of $66.56 billion, a price-to-earnings ratio of 38.12, a PEG ratio of 1.65 and a beta of 0.40. The company has a fifty day simple moving average of $232.20 and a 200-day simple moving average of $233.99. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BDX shares. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson purchased 1,500 shares of the stock in a transaction dated Monday, February 10th. The shares were purchased at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the transaction, the director now owns 8,015 shares in the company, valued at approximately $1,872,464.30. The trade was a 23.02 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 9,844 shares of company stock valued at $2,210,716 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.